Ocular Changes in Patients Using Tirzepatide or Semaglutide

Conditions studied

Type 2 Diabetes Mellitus, Obesity

About this study

This prospective observational study aims to evaluate ocular structural and microvascular changes in adults with obesity who are receiving semaglutide or tirzepatide as part of routine clinical care. Participants with and without type 2 diabetes mellitus will be included. Participants will undergo ophthalmologic examinations at baseline and during follow-up. Changes in optic nerve head parameters, retinal thickness, retinal and choroidal microvascular parameters, and choroidal thickness will be assessed using optical coherence tomography (OCT), optical coherence tomography angiography (OCT-A), and other routine ophthalmologic examination methods. The study will compare ocular measurements obtained at baseline and during follow-up to investigate changes associated with semaglutide or tirzepatide treatment over a period of up to 18 months.

Interventions

• Drug: Semaglutide — Semaglutide is prescribed as part of routine clinical care. Treatment is not assigned by the study protocol. Ocular structural and vascular parameters are evaluated before treatment and during follow-up.
• Drug: Tirzepatide — Tirzepatide is prescribed as part of routine clinical care. Treatment is not assigned by the study protocol. Ocular structural and vascular parameters are evaluated before treatment and during follow-up.

Primary outcomes

• Change in Retinal Nerve Fiber Layer Thickness (Baseline to up to 18 months)
• Change in Retinal Thickness (Baseline to up to 18 months)
• Change in Superficial Retinal Vessel Density (Baseline to 18 months)
• Change in Deep Retinal Vessel Density (Baseline to 18 months)
• Change in Foveal Avascular Zone Area (Baseline to 18 months)
• Change in Choriocapillaris Flow Deficit Percentage (Baseline to 18 months)